Shots:

• The approval is based on a P-III APSEN study involve assessing Brukinsa vs ibrutinib in 201 patients with r/r or TN WM who harbor an MYD88 mutation (MYD88MUT). The recommended dose of the therapy is 320mg and is expected to be available in Canada imminently
• The P-III APSEN study demonstrated clinical benefit with advantages in safety- the combined CR + VGPR rate in the overall ITT population was 28.4% vs 19.2% as assessed by IRC per adaptation of the response criteria updated at the 6th IWWM
• Brukinsa (BGB-3111) is a BTK inhibitor- currently being evaluated in multiple clinical studies globally as a monothx. or in combination with other therapies targeting B cell malignancies

 ­ Ref: Businesswire  | Image: Businesswire